• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Evolution of Auto-Substitution in Biosimilar Landscape


Professionals speak to auto-substitution and its Impact on the shared decision-making process associated with biosimilars.

This is a video synopsis/summary of a panel discussion involving distinguished experts in the medical field: Ryan Haumschild, PharmD, MS, MBA; Alice B. Gottlieb, MD, PhD; Bincy Abraham, MD, MS; Jamie T. Brogan, APRN; and Vibeke Strand, MD. The focus of this segment is on interchangeability studies and automatic substitution.

Haumschild initiates the discussion by emphasizing the importance of understanding interchangeability studies in the context of biosimilars. Haumschild delves into the evolving landscape of biosimilars, stressing the need for robust clinical data to establish interchangeability.

Brogan provides a practical perspective on automatic substitution. She discusses the challenges faced by health care providers, emphasizing the potential impact on patient care. She underscores the importance of transparent communication in navigating the complexities associated with automatic substitution.

Gottlieb contributes insights into the intricacies of interchangeability studies. She highlights the challenges associated with extrapolating data and underscores the need for comprehensive studies to ensure the safety and efficacy of biosimilars.

Video synopsis is AI-generated and reviewed by editorial staff.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.